Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Schambach

Showing results (11-20 of 358) with videos related to

Pageof 36
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 13, 2016
Gene Insertion Into Genomic Safe Harbors for Human Gene TherapyEirini P Papapetrou, Axel Schambach
Human Gene Therapy|August 30, 2018
Chimeric Antigen Receptor T Cells: Extending Translation from Liquid to Solid TumorsMichael A Morgan, Axel Schambach
Frontiers in Immunology|November 14, 2018
Engineering CAR-T Cells for Improved Function Against Solid TumorsMichael A Morgan, Axel Schambach
Cellular and Molecular Life Sciences : CMLS|February 9, 2021
The hemogenic endothelium: a critical source for the generation of PSC-derived hematopoietic stem and progenitor cellsLucas Lange, Michael Morgan, Axel Schambach
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 25, 2021
Two cases of T cell lymphoma following Piggybac-mediated CAR T cell therapyAxel Schambach, Michael Morgan, Boris Fehse
Frontiers in Immunology|January 6, 2023
Editorial: Engineered immune cells in cancer immunotherapy (EICCI)Francisco Martin, Axel Schambach, Cristina Maccalli
Journal of Virology|January 19, 2007
New way of regulating alternative splicing in retroviruses: the promoter makes a differenceJens Bohne, Axel Schambach, Daniela Zychlinski
Frontiers in Immunology|May 6, 2026
Editorial: Community Series in Engineered Immune Cells in Cancer Immunotherapy (EICCI), volume IIAxel Schambach, Francisco Martin, Cristina Maccalli
Current Gene Therapy|September 1, 2012
Retroviral protein transfer: falling apart to make an impactTobias Maetzig, Christopher Baum, Axel Schambach
Experimental Hematology|August 12, 2018
Fluorescent genetic barcoding for cellular multiplex analysesTobias Maetzig, Michael Morgan, Axel Schambach
Pageof 36

Showing results (11-20 of 358) with videos related to

Sort By:
Pageof 36
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 13, 2016
Gene Insertion Into Genomic Safe Harbors for Human Gene TherapyEirini P Papapetrou, Axel Schambach
Human Gene Therapy|August 30, 2018
Chimeric Antigen Receptor T Cells: Extending Translation from Liquid to Solid TumorsMichael A Morgan, Axel Schambach
Frontiers in Immunology|November 14, 2018
Engineering CAR-T Cells for Improved Function Against Solid TumorsMichael A Morgan, Axel Schambach
Cellular and Molecular Life Sciences : CMLS|February 9, 2021
The hemogenic endothelium: a critical source for the generation of PSC-derived hematopoietic stem and progenitor cellsLucas Lange, Michael Morgan, Axel Schambach
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 25, 2021
Two cases of T cell lymphoma following Piggybac-mediated CAR T cell therapyAxel Schambach, Michael Morgan, Boris Fehse
Frontiers in Immunology|January 6, 2023
Editorial: Engineered immune cells in cancer immunotherapy (EICCI)Francisco Martin, Axel Schambach, Cristina Maccalli
Journal of Virology|January 19, 2007
New way of regulating alternative splicing in retroviruses: the promoter makes a differenceJens Bohne, Axel Schambach, Daniela Zychlinski
Frontiers in Immunology|May 6, 2026
Editorial: Community Series in Engineered Immune Cells in Cancer Immunotherapy (EICCI), volume IIAxel Schambach, Francisco Martin, Cristina Maccalli
Current Gene Therapy|September 1, 2012
Retroviral protein transfer: falling apart to make an impactTobias Maetzig, Christopher Baum, Axel Schambach
Experimental Hematology|August 12, 2018
Fluorescent genetic barcoding for cellular multiplex analysesTobias Maetzig, Michael Morgan, Axel Schambach
Pageof 36